Delisting riskPopularity #3,103
Invivyd (IVVD)
Develops monoclonal antibodies for serious viral diseases, beginning with COVID-19 prevention.
$0.9400
vs last close−0.02 (−2.49%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 78.97% | 232.76M shares | |
|---|---|---|---|
| 133 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 5.20% | 15.34M shares | |
| 8 holders · as of Aug 18, 2026 | |||
| Strategic holders | 6.87% | 20.26M shares | |
| 1 holder · as of Dec 29, 2025 | |||
| Other | ≈ 8.96% | 26.40M shares | |
| remainder | |||
294.76M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
133 holders · 232.76M shares · 36 new positions · 75 increased · 26 reduced · 48 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Jupiter Topco LLC | 34.17M | 11.59% | +34.17Mnew | Aug 14, 2026 |
| BVF Inc/IL | 28.17M | 9.56% | +8.64M | Aug 14, 2026 |
| Maverick Capital Ltd | 18.97M | 6.44% | 0 | Aug 14, 2026 |
| Perceptive Advisors LLC | 18.49M | 6.27% | −2.37M | Aug 14, 2026 |
| BlackRock, Inc. | 16.13M | 5.47% | +11.85M | Aug 7, 2026 |
| Vanguard Capital Management LLC | 10.50M | 3.56% | +422.2K | Aug 13, 2026 |
| M28 Capital Management LP | 9.25M | 3.14% | 0 | Aug 13, 2026 |
| Saturn V Capital Management LLC | 8.39M | 2.85% | −2.56M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 12.10% | 25.38M | 13G | Nov 14, 2025 |
| Perceptive Advisors LLC | 7.90% | 21.79M | 13G | Nov 25, 2025 |
| Adimab, LLC | 7.30% | 20.26M | 13D | Dec 29, 2025 |
| RA Capital Management, L.P. | 7.00% | 21.34M | 13G | May 15, 2026 |
| Maverick Capital, Ltd. | 6.70% | 18.97M | 13G | Feb 13, 2026 |
| BlackRock, Inc. | 5.50% | 16.12M | 13G | Jul 28, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 18, 2026 | Robert D. III Allenofficer: Chief Scientific Officer | Sale | 17,043 | $0.8429 | 178,765 |
| Aug 17, 2026 | Robert D. III Allenofficer: Chief Scientific Officer | Sale | 20,679 | $0.7220 | 195,808 |
| Aug 18, 2026 | Jill Andersenofficer: Chief Legal Officer, Secretary | Sale | 30,706 | $0.8429 | 283,774 |
| Aug 17, 2026 | Jill Andersenofficer: Chief Legal Officer, Secretary | Sale | 37,256 | $0.7220 | 314,480 |
| Aug 18, 2026 | William E. Dukeofficer: Chief Financial Officer | Sale | 18,425 | $0.8429 | 168,937 |
| Aug 17, 2026 | William E. Dukeofficer: Chief Financial Officer | Sale | 22,355 | $0.7220 | 187,362 |
| Aug 18, 2026 | Julie Greenofficer: Chief Human Resources Officer | Sale | 18,425 | $0.8429 | 168,937 |
| Aug 17, 2026 | Julie Greenofficer: Chief Human Resources Officer | Sale | 22,355 | $0.7220 | 187,362 |
| Aug 18, 2026 | Timothy Edward Leeofficer: Chief Commercial Officer | Sale | 18,425 | $0.8429 | 178,937 |
| Aug 17, 2026 | Timothy Edward Leeofficer: Chief Commercial Officer | Sale | 22,355 | $0.7220 | 197,362 |
House and Senate disclosures
Not reported.